Head and Neck Tumors Clinical Trial
Official title:
Study of the ISotopic Repartition of cOpper in Head and Neck TumOral and lymPhomatous pathologiEs
The distribution of stable (non-radioactive) isotopes in living organisms is increasingly
studied, in particular the zinc (Zn), copper (Cu) and iron (Fe), not only in primitive
organisms, but also in mammals.
The scientific community shows a growing interest in the study of the isotopic distribution
of Cu in humans: this distribution can vary according to gender or nutrition. Concerning
pathology, the isotopic distribution of Cu seems interesting in Wilson's disease or in
cirrhosis.
Additionally, a promising area of study focuses on the role of Cu in cancerous tumors,
neoangiogenesis, the mechanisms of free radicals reduction and signaling pathways.
Head and neck cancers are sensitive to platinum salts. Links between platinum and Cu are
important: platinum penetrates into the cell through a Cu receptor, it interacts with the
regulation mechanisms of Cu and platinum.
Preliminary studies suggest a variation of the measurable isotopic distribution of Zn in
patients with breast tumor and of Cu in patients presenting breast as well as colorectal
tumors.
The Larner et al. study suggest a promising role of Zn in breast cancer, indeed, results
highlight a variation of distribution of Zn in 10 breast tumors. Concerning the study of
Télouk et al. on 8 patients presenting colorectal tumors and 20 patients presenting breast
tumors, results are in favor of an increase of mortality when Cu 65 is decreased in the serum
and the isotopic modifications happen earlier than usual modifications of biochemical tumor
markers such as: carbohydrate antigen (CA) 19.9, Carcinoma Antigen (CA) 15.3,
Carcinoembryonic antigen (CEA).
Currently, there is no information about the distribution of the stable isotopes of Cu in
head and neck tumors.
The objective of the study is to determine if the distribution of 65Cu / 63Cu is modified in
tumoral tissues compared to healthy tissues. The isotopic distribution of the Cu in 2 tumor
types, head and neck tumors and lymphomas, will be also investigated in order to determine if
this distribution is specific of a tumor type or not.
In case of positivity of this variation, the prognostic interest of these parameters will be
evaluated.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05758389 -
Tislelizumab Combined APF Chemotherapy in the Treatment of Locally Advanced Head and Neck Tumors
|
Phase 2 | |
| Completed |
NCT01019954 -
Photodynamic Therapy for Early Head and Neck Tumors
|
Phase 1 | |
| Recruiting |
NCT06224166 -
Analysis of HPV and Biomarkers Present in the Biological Fluids of Patients Suffering From Head and Neck Cancer as a Non-invasive Strategy for Detecting Recurrence
|
||
| Recruiting |
NCT05671458 -
Multiparametric Imaging-based Intraoperative Navigation for Guidance of Surgical Resection and Postoperative Radiotherapy in Patients With Head-and-neck Tumors
|
N/A | |
| Terminated |
NCT00528294 -
Phase I Trial From GRID 18F-FDG-PET Biological Imaging-guided Intensitymodulated Radiotherapy (BG-IMRT) With Patients With Recurrent or New Head or Neck Tumor in Previously Radiated Area
|
Phase 1 | |
| Recruiting |
NCT04671485 -
Effectiveness of autoHYpnosis in the Prevention of Anxiety During Radiotherapy of Head and Neck Tumors (HYMACO)
|
N/A | |
| Completed |
NCT02855723 -
Randomized, Open-label Economic and Medical Study on the Lymph Node Management of Squamous Cell Carcinoma of the Oral Cavity and Oropharynx Tumor Stage 1 or 2, Nodes 0 (T1-T2 N0) Operable
|
N/A |